Download image:

Josephine A. Mauskopf

Vice President of Health Economics, RTI-HS

Josephine Mauskopf, PhD, MHA, has extensive experience both as a consultant and within the pharmaceutical industry designing and implementing pharmacoeconomic research strategies. She has designed pharmacoeconomic research programs for drugs for bacterial infections, viral infections, psychiatric illness, and neurologic diseases. Dr. Mauskopf has estimated budget impacts for new products for schizophrenia, bipolar disease, breast cancer, and HIV infection. She has estimated the cost-effectiveness of antiretroviral drugs, as well as drugs for treating herpes zoster, epilepsy, neonatal respiratory distress syndrome, digoxin toxicity, community-acquired pneumonia, intra-abdominal infections, and primary pulmonary hypertension. Dr. Mauskopf was previously vice president at MEDTAP International, department head of Economics Research at Burroughs Wellcome, and director of Pharmacoeconomics Research for anti-virals and anti-infectives at Glaxo Wellcome. She completed 8 years as editor in chief of Value in Health. She has presented her research at numerous national and international symposia, and has published extensively in journals.


PhD, Economics, Duke University; MHA, Health Administration, Duke University; MA, Physiology and Pharmacology, Duke University.

Latest Publications

Mauskopf, J., Fay, M., Iyer, R., Sarda, S., & Livingston, T. (2015). Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States. Journal of Medical Economics, Advance Online Publication .
Mauskopf, J.A., Graham, J., Fay-Azhar, M., & Kinter, E. (2015). Budget impact of adding peginterferon beta-1A to the formulary for the treatment of relapsing forms of multiple sclerosis, Value in Health, 18 (3):A280-A281.
Husereau, D., Drummond, M., Petrou, S., Greenberg, D., Mauskopf, J., Augustovski, F., et al. (2015). Reply to Roberts et al.: CHEERS is sufficient for reporting cost-benefit analysis, but may require further elaboration. Pharmacoeconomics, 33 (5):535-536.
Talbird, S.E., Mauskopf, J.A., & Yang, H.K. (2015). Review of cost-effectiveness analyses of varicella vaccination: Which model structure assumptions and input parameters matter?, Value in Health, 18 (3):A14-A15.
Mauskopf, J.A., Mitchell, S., Samuel, M., & Samp, J.C. (2015). Systematic literature review to identify cost estimates of liver disease in those with chronic hepatitis C virus (Hcv) in the United States, Value in Health, 18 (3):A236-A236.
View all publications by Josephine A. Mauskopf (207)


  • Health Economics
  • Burden of Illness Literature Reviews
  • Economic Analyses of Health Care Interventions
  • Health Policy Analyses